Telix Pharmaceuticals (TLPPF) Price & Analysis

Compare

155 Followers

TLPPF Stock Chart & Stats

$7.72

$0.06(0.36%)

At close: Jan 08 4:00 PM EST

$7.72

$0.06(0.36%)

Day’s Range― - ―

52-Week Range$6.95 - $24.85

Previous CloseN/A

Volume500.00

Average Volume (3M)3.20K

Market Cap

$2.61B

Enterprise Value$8.56B

Total Cash (Recent Filing)$207.16M

Total Debt (Recent Filing)$418.25M

Price to Earnings (P/E)232.5

Beta1.48

Next Earnings

Jan 20, 2026

EPS Estimate

0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding338,777,040

10 Day Avg. Volume2,583

30 Day Avg. Volume3,199

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)14.35

Price to Sales (P/S)10.41

P/FCF Ratio906.02

Enterprise Value/Market Cap3.28

Enterprise Value/Revenue7.21

Enterprise Value/Gross Profit12.69

Enterprise Value/Ebitda99.84

Forecast

1Y Price Target

$17.64

Price Target Upside128.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial EnrollmentBiPASS phase three dosing of U.S. patients enhances enrollment momentum and improves the diversity and statistical strength of data supporting Telix's prostate cancer imaging agent.

Diagnostic Label ExpansionTesting MRI together with Telix's imaging agent for initial prostate cancer diagnosis could support an expanded approved indication and increase the total number of scans using the agent.

International Recruitment And Commercial ReadinessSwift recruitment in Australia combined with North American patient inclusion strengthens clinical validation and helps position Telix for broader market adoption if trial results are favorable.

Bears Say

Regulatory And Guideline UncertaintyFuture upside depends on obtaining regulatory approvals and favorable placement in clinical guidelines, creating uncertainty about eventual market access for the imaging product.

Safety Review And Regulatory/legal ScrutinyAn unresolved safety data read, the possibility of a product resubmission, and an ongoing SEC probe could raise investor concerns and exert downward pressure on the stock.

Valuation Pressure From Analyst ActionsA reduced analyst price target reflects diminished market confidence and could contribute to further valuation pressure on Telix shares.

Telix Pharmaceuticals News

Telix Hits FY2025 Revenue Guidance on Gozellix Momentum, Advances Radiopharma Pipeline

Telix Pharmaceuticals ( ($AU:TLX) ) has provided an announcement. Telix Pharmaceuticals reported unaudited full-year 2025 revenue of approximately...

12h ago

Telix’s Illuccix Prostate Cancer Imaging NDA Accepted for Review in China

Telix Pharmaceuticals ( ($AU:TLX) ) has provided an announcement. Telix Pharmaceuticals and its Greater China partner Grand Pharmaceutical...

21h ago

Telix Corrects ASX Filing on Option Exercise and Share Issuance

Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an announcement. Telix Pharmaceuticals has corrected an earlier Appendix 2A filing...

7d ago

Telix Pharmaceuticals Reports Lapse of Unvested Share Rights and Appreciation Rights

Telix Pharmaceuticals ( ($AU:TLX) ) has provided an update. Telix Pharmaceuticals has announced the lapse of several classes...

8d ago

Telix Publishes J.P. Morgan Conference Deck and Sets Date for Q4 2025 Results

Telix Pharmaceuticals ( ($AU:TLX) ) has shared an update. Telix Pharmaceuticals has released the investor presentation that Managing...

8d ago

Telix Issues Over 2.5 Million Unquoted Share Appreciation Rights Under Incentive Plan

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals has notified the market of the issuance...

28d ago

Telix Seeks ASX Quotation for Additional Ordinary Shares After Option Conversions

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals has applied to the ASX for quotation...

28d ago

Telix Advances Precision Imaging Portfolio With Strong China Trial Data and FDA Progress

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals reported strong top-line Phase 3 data from...

30d ago

Telix Pharmaceuticals Facing Class Action after Cancer Claims Raise Investor Concerns

A class action lawsuit was filed against Telix Pharmaceuticals ($TLPPF) on November 10, 2025. The plaintiffs (shareholders) allege...

1M ago

Telix Advances ProstACT Global Phase 3 Prostate Cancer Study

Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals has provided an update on its ProstACT...

1M ago

Telix Pharmaceuticals announces Health Canada approval of Illuccix

Telix Pharmaceuticals announces that Health Canada has approved the use of Illuccix in selecting patients for PSMA1-targeted radionuclide...

1y ago

Telix Pharmaceuticals announces first patient dosed in Phase II CA-NINE trial

Telix Pharmaceuticals announces that the first patient has been dosed in a Phase II trial exploring the clinical...

1y ago

Telix Pharmaceuticals to acquire RLS

Telix Pharmaceuticals and RLS, America’s only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals, announced an...

1y ago

Telix announces Cardinal Health as U.S. commercial distributor for Zircaix

Telix Pharmaceuticals has selected Cardinal Health as a commercial radiopharmaceutical distributor to supply finished unit doses of its...

1y ago

CAH

TLPPF FAQ

What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?

Telix Pharmaceuticals Ltd. lowest stock price was $6.95 and its highest was $24.85 in the past 12 months.

What is Telix Pharmaceuticals Ltd.’s market cap?

Telix Pharmaceuticals Ltd.’s market cap is $2.61B.

When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?

Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Jan 20, 2026 which is today.

How were Telix Pharmaceuticals Ltd.’s earnings last quarter?

Currently, no data Available

Is Telix Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Telix Pharmaceuticals Ltd. pay dividends?

Telix Pharmaceuticals Ltd. does not currently pay dividends.

What is Telix Pharmaceuticals Ltd.’s EPS estimate?

Telix Pharmaceuticals Ltd.’s EPS estimate is 0.03.

How many shares outstanding does Telix Pharmaceuticals Ltd. have?

Telix Pharmaceuticals Ltd. has 338,777,040 shares outstanding.

What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in TLPPF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Telix Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

3.21%

Trailing 12-Months

Asset Growth

138.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Telix Pharmaceuticals (TLPPF) Earnings & Revenues

Historic Earnings Reports

TLPPF Stock 12 Month Forecast

Average Price Target

$17.64

▲(128.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","23":"$23","10.25":"$10.25","14.5":"$14.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.8276,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.4138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10.25,14.5,18.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.58,8.752892307692308,9.925784615384615,11.098676923076923,12.27156923076923,13.444461538461539,14.617353846153847,15.790246153846153,16.963138461538463,18.13603076923077,19.30892307692308,20.481815384615384,21.654707692307692,{"y":22.8276,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.58,8.353846153846154,9.127692307692307,9.901538461538461,10.675384615384615,11.44923076923077,12.223076923076924,12.996923076923077,13.77076923076923,14.544615384615385,15.318461538461538,16.092307692307692,16.866153846153846,{"y":17.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.58,7.874907692307692,8.169815384615385,8.464723076923077,8.75963076923077,9.054538461538462,9.349446153846154,9.644353846153846,9.939261538461539,10.234169230769231,10.529076923076923,10.823984615384616,11.118892307692308,{"y":11.4138,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.58,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >